- Condition: Prostate Cancer
Intervention: Drug: Saw Palmetto
Sponsors: Michigan State University; Michigan State University
Recruiting - verified April 2012 - Conditions: Muscle Atrophy; ACL Reconstruction; Trauma; Osteoarthritis
Interventions: Drug: Testosterone; Drug: Saline
Sponsors: University of Southern California; University of Southern California; Boston University; University of Oregon
Recruiting - verified May 2012 - Condition: Peyronie's Disease
Interventions: Drug: Vitamin D2; Drug: Vitamin E; Drug: Testosterone Pellets
Sponsors: Men's Health Boston; Men's Health Boston
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Androgen Ablation; Drug: Cabazitaxel; Drug: Salvage Therapy; Drug: Neoadjuvant Treatment - Hormonal Therapy; Drug: Neoadjuvant Treatment - Cabazitaxel
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Klinefelter Syndrome; XXY Syndrome
Interventions: Drug: Testosterone gel 1%; Drug: Placebo gel
Sponsors: University of Colorado, Denver; University of Colorado, Denver; Colorado Clinical & Translational Sciences Institute; Children's Hospital Colorado; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012 - Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: atorvastatin calcium; Drug: placebo
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Secondary Hypogonadism; Low Testosterone
Interventions: Drug: enclomiphene citrate; Drug: Placebo; Drug: Testosterone
Sponsors: Repros Therapeutics Inc.; Repros Therapeutics Inc.
Not yet recruiting - verified April 2012 - Conditions: Secondary Hypogonadism; Low Testosterone
Interventions: Drug: enclomiphene citrate; Drug: Testosterone
Sponsors: Repros Therapeutics Inc.; Repros Therapeutics Inc.
Not yet recruiting - verified April 2012 - Condition: Adenocarcinoma of the Prostate
Interventions: Radiation: Radiation Therapy; Drug: Androgen Suppression Therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Intervention: Biological: Ipilimumab
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Radiation: Proton Radiation; Drug: Androgen Suppression Therapy
Sponsors: Proton Collaborative Group; Proton Collaborative Group
Recruiting - verified January 2012 - Conditions: Prostate Cancer Metastatic; Hormone Refractory Prostate Cancer
Interventions: Biological: sipuleucel-T; Drug: abiraterone acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Procedure: Sodium Flouride (NaF) Positron Emission Tomograpy/Computed Tomography (PET/CT) imaging
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Drug: Radiation; Drug: Androgen Deprivation Therapy (ADT); Other: Standard of care; Drug: L-BLP25
Sponsors: EMD Serono; EMD Serono
Recruiting - verified December 2011 - Condition: Hypogonadal Males
Interventions: Drug: Testosterone (FE 999303); Drug: Testosterone (FE 999303)
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Polycystic Ovary Syndrome; Hyperandrogenism
Interventions: Drug: Flutamide; Drug: Progesterone; Drug: estrace (estradiol)
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified September 2011 - Conditions: Hypogonadism; Osteopenia; Osteoporosis
Interventions: Drug: Testosterone; Drug: Alendronate; Drug: Placebo Alendronate; Drug: Placebo Testosterone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Endo Pharmaceuticals; Merck
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel; Radiation: Intensity Modulated Radiation Therapy (IMRT); Drug: Anti-Androgen Therapy: Bicalutamide; Genetic: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Male Hypogonadism
Interventions: Drug: Testosterone; Drug: Testosterone
Sponsors: Trimel Biopharma SRL; Trimel Biopharma SRL
Recruiting - verified October 2011 - Condition: Aplastic Anemia
Intervention: Drug: Danazol
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Spironolactone; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Leuprolide; Drug: Dexamethasone; Drug: recombinant human chorionic gonadotropin
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin (ACTH)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Polycystic Ovary Syndrome; Obesity
Interventions: Drug: Dexamethasone; Drug: Cortrosyn
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of California, San Diego
Recruiting - verified August 2011 - Conditions: Polycystic Ovary Syndrome; Obesity; Hyperandrogenism
Interventions: Drug: Dexamethasone; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia; University of California, San Diego
Recruiting - verified August 2011 - Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: Placebo; Drug: Sildenafil; Drug: Testosterone
Sponsors: Emotional Brain NY Inc.; Emotional Brain NY Inc.
Recruiting - verified September 2011 - Conditions: Ejaculatory Dysfunction; Hypogonadism
Interventions: Drug: Testosterone Solution 2%; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma
Interventions: Biological: sipuleucel-T; Drug: leuprolide acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Sponsors: GP-Pharm; GP-Pharm
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Other: ADT Therapy; Drug: Axitinib; Procedure: Prostatectomy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012 - The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older MenCondition: Sarcopenia
Interventions: Drug: Testosterone enanthate; Drug: Testosterone enanthate; Drug: Placebo
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate; Drug: Dutasteride; Drug: Prednisone
Sponsors: Dana-Farber Cancer Institute; Mary-Ellen Taplin, MD
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Hypogonadism
Interventions: Drug: Testosterone Cypionate; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012 - Conditions: Heart Failure; Hypogonadism
Intervention: Drug: testerone gel
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Abbott
Not yet recruiting - verified April 2011 - Condition: Prostatic Neoplasm
Intervention: Drug: EZN-4176
Sponsors: Enzon Pharmaceuticals, Inc.; Enzon Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Conditions: Healthy Men; Male Contraception
Interventions: Drug: Dimethandrolone Undecanoate; Drug: Placebo
Sponsors: Los Angeles Biomedical Research Institute; Los Angeles Biomedical Research Institute; National Institutes of Health (NIH); University of Washington
Recruiting - verified March 2012 - Condition: Healthy
Intervention: Drug: Testosterone 1% gel (or placebo) + acyline (or placebo)
Sponsors: University of Washington; University of Washington; National Institutes of Health (NIH); National Institute on Aging (NIA)
Not yet recruiting - verified June 2011 - Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: bicalutamide; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Mobility Limitation
Interventions: Drug: Testosterone enanthate; Drug: Testosterone enanthate
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified July 2011 - Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate; Drug: Prednisone; Drug: Sunitinib; Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb; Ortho Biotech, Inc.; Pfizer
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Prostate Cancer
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified January 2012 - Condition: Healthy Males
Interventions: Drug: Acyline; Drug: Testosterone gel applied transdermally for 10 days; Drug: ketoconazole; Drug: Ketoconazole; Drug: Dutasteride; Drug: Anastrozole
Sponsors: University of Washington; University of Washington; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Condition: Prostate Cancer
Intervention: Drug: ARN-509
Sponsors: Aragon Pharmaceuticals, Inc.; Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Testosterone; Trauma; Brain Injury
Interventions: Drug: Androgel (Testosterone Gel); Drug: Androgel Placebo
Sponsors: Craig Hospital; Craig Hospital; University of Colorado, Denver
Recruiting - verified February 2012 - Conditions: Androgen Deficiency; AD; Erectile Dysfunction; ED; Cardiovascular Adverse Events; Cerebrovascular Adverse Events
Intervention:
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011 - Condition: Obesity
Interventions: Drug: Leuprolide; Drug: Testosterone
Sponsors: Mayo Clinic; Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Abbott
Recruiting - verified January 2012 - Conditions: Hypogonadotropic Hypogonadism; Type 2 Diabetes
Interventions: Drug: testosterone; Drug: clomiphene; Drug: placebo; Drug: placebo
Sponsors: State University of New York at Buffalo; State University of New York at Buffalo; American Diabetes Association
Recruiting - verified July 2011 - Condition: PCOS
Interventions: Drug: Dexamethasone and recombinant hCG; Drug: dexamethasone, human chorionic gonadotrpoin (hCG)
Sponsors: University of California, San Diego; University of California, San Diego; University of Virginia
Recruiting - verified August 2011 - Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Anorexia Nervosa; Eating Disorder; Anxiety; Depression
Interventions: Drug: Testosterone; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Mental Health (NIMH)
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Testosterone; Drug: Etoposide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified May 2012 - Conditions: Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: bicalutamide; Drug: raloxifene; Procedure: quality-of-life assessment
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified January 2012 - Condition: Development
Intervention: Drug: Cosyntropin 0.25 mg
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified August 2011 - Condition: Prostate Cancer
Interventions: Radiation: Proton Therapy , proton boost and docetaxel followed by androgen deprivation; Radiation: Conformal X-ray , proton boost and docetaxel followed by androgen deprivation
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Conditions: Adenocarcinoma of the Prostate; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Drug: leuprolide acetate; Other: mass spectrometry; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Radiation: external beam radiation therapy; Drug: goserelin acetate
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Radiation: 3-D Ultrasound; Drug: hCG with and without FSH; Drug: Adrenocorticotropin (ACTH) infusion; Drug: Diazoxide and hCG
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified August 2011 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: IV administration of fluorine-18 methylcholine followed by PET/CT imaging
Sponsors: Queen's Medical Centre; Queen's Medical Centre; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Sarcopenia
Interventions: Drug: Testosterone injection; Drug: Testosterone gel
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified May 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Flutamide; Drug: Placebo
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: leuprolide acetate; Drug: goserelin; Other: laboratory biomarker analysis; Other: quality-of-life assessment; Other: pharmacological study
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Condition: Hyperandrogenism
Intervention:
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Conditions: Prostate Cancer; Prostatic Neoplasms
Interventions: Drug: Panobinostat (Phase II doses); Drug: Panobinostat
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis
Recruiting - verified March 2012 - Conditions: Cachexia; Cervical Cancer
Interventions: Drug: Standard of Care Chemotherapy and/or Radiation plus Placebo (Saline) Testosterone; Drug: Arm II: Standard of Care Chemotherapy and/or Radiation plus Testosterone Enanthate
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Low Testosterone Levels; Erectile Dysfunction
Interventions: Drug: Testim® + Viagra®; Drug: Placebo Testim® + Viagra®
Sponsors: Baylor College of Medicine; Mohit Khera
Recruiting - verified December 2011 - Condition: Prostate Cancer
Interventions: Drug: Androgen Deprivation Therapy; Drug: bicalutamide; Drug: bevacizumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Genentech; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Cancer Institute of New Jersey
Recruiting - verified February 2012 - Conditions: Polycystic Ovary Syndrome; Obstructive Sleep Apnea; Obesity
Interventions: Drug: Progesterone; Drug: testosterone; Drug: glucocorticoid; Device: continuous positive airway pressure; Drug: Estrogens
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified February 2012 - Condition: Andropause
Intervention: Drug: AndroGel® (testosterone gel)
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute on Aging (NIA); National Institute of Neurological Disorders and Stroke (NINDS); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Heart, Lung, and Blood Institute (NHLBI); Abbott
Recruiting - verified January 2012 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: ganirelix acetate; Drug: methyl testosterone
Sponsors: Yale University; Yale University
Recruiting - verified August 2011 - Condition: Ovarian Cancer
Intervention: Drug: flutamide
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified September 2010 - Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate CancerCondition: Prostate Cancer
Interventions: Drug: Dutasteride; Drug: Placebo
Sponsors: NorthShore University HealthSystem Research Institute; NorthShore University HealthSystem Research Institute; University of Chicago; Northwestern University
Recruiting - verified April 2008 - Conditions: Aging; Insulin Resistance
Interventions: Drug: Testosterone; Drug: Estrogen
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified January 2012 - Condition: Prostate Cancer
Intervention: Drug: Revlimid
Sponsors: Oncology Specialists, S.C.; Oncology Specialists, S.C.; Celgene Corporation
Recruiting - verified August 2010 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Behavioral: Questionaires; Behavioral: Questionaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); City of Hope National Medical Center; Fordham University; Columbia University; New York University Medical Center
Recruiting - verified March 2012 - Condition: Burns
Interventions: Procedure: Stable Isotope Infusion Study; Procedure: Collection of blood and tissues; Procedure: Radiology testing: DEXA, K+ counter, ultrasound, MRI; Drug: Humatrope; Drug: Ketoconazole; Drug: Oxandrolone; Drug: Propranolol; Drug: Oxandrolone and propranolol combined; Drug: Humatrope and propranolol combined; Drug: Placebo; Behavioral: Exercise--Hospital supervised intensive exercise program; Behavioral: Home exercise program
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; U.S. Department of Education; National Institutes of Health (NIH); Shriners Hospitals for Children
Recruiting - verified March 2012 - Condition: Prostate Cancer
Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: RAD001, Docetaxel, Bevacizumab
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; Novartis; Genentech; University of Southern California
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Flutamide; Biological: Sargramostim; Biological: recombinant fowlpox-prostate apecific antigen vaccine; Biological: recombinant vaccinia prostate specific antigen vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Prostate Cancer
Interventions: Radiation: Samarium Sm 153 lexidronam pentasodium; Biological: Sargramostim; Biological: Recombinant vaccinia-TRICOM vaccine; Biological: Recombinant fowlpox-TRICOM vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Polycystic Ovary Syndrome; Metabolic Syndrome
Interventions: Drug: Metformin; Drug: flutamide; Drug: drospirenone; Other: placebo
Sponsors: Northwestern University; Northwestern University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention: Drug: Gleevec + Sorafenib
Sponsors: Oncology Specialists, S.C.; Oncology Specialists, S.C.
Recruiting - verified August 2010 - Condition: Prostate Cancer
Intervention: Drug: Sorafenib
Sponsors: Oncology Specialists, S.C.; Oncology Specialists, S.C.
Recruiting - verified August 2010 - Condition: Coronary Artery Disease
Interventions: Drug: AndroGel 5 Grams; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; Abbott
Recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: physiologic testing; Procedure: computed tomography
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified October 2006 - Conditions: Aging; Obesity; Insulin Resistance; Hypogonadism
Intervention: Drug: Topical testosterone (Androgel) 10 g/day
Sponsors: University of Southern California; University of Southern California; Solvay Pharmaceuticals
Recruiting - verified July 2011 - Condition: Klinefelter Syndrome
Interventions: Drug: androgen oxandrolone; Other: placebo
Sponsors: Thomas Jefferson University; Thomas Jefferson University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified July 2011 - Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Excess Androgen; Congenital Adrenal Hyperplasia (CAH); Familial Male-Limited Precocious Puberty (FMPP)
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Androgen Hormonal Suppression and Radiation; Drug: Androgen Suppression Therapy and Radiation Therapy
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Sanofi-Aventis
Recruiting - verified June 2011 - Condition: Healthy Volunteers
Interventions: Drug: Testosterone; Drug: Testosterone; Drug: Anastrazole; Drug: Goserelin acetate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute on Aging (NIA); Solvay Pharmaceuticals; AstraZeneca
Recruiting - verified April 2012
 |
Androgen Antagonists Clinical Trials |
